Table 1. Characteristics of included studies.
| Study | Study Type | Number of eyes | Intervention | Follow-Up (months)** | Ocular complication requiring retreatment | Ocular complication without the need of retreatment |
|---|---|---|---|---|---|---|
| Bancalari, 2014 [19] | retrospective | 24 | Bevacizumab | 12 | 8 (33.3%) | 1 (4.2%) |
| Chen, 2014 [20] | retrospective | 72 | Ranibizumab Bevacizumab | 12 | 0 (0%) | 0 (0%) |
| Chen, 2014 [21] | retrospective | 57* | Bevacizumab w/ or w/o Laser coagulation | 24 | - | - |
| Cheng, 2014 [22] | retrospective | 13 | Bevacizumab | - | 1 (7.7%) | 0 (0%) |
| Geloneck, 2014 [23] | Follow-Up of Mintz-Hittner (38) | 211* | Bevacizumab Laser coagulation | 30 | - | - |
| Harder, 2014 [24] | retrospective | 57 | Bevacizumab | - | 1 (1.8%) | 0 (0%) |
| Henaine-Berra, 2014 [25] | prospective, non-randomized | 46 | Bevacizumab | - | 0 (0%) | 0 (0%) |
| Kuniyoshi, 2014 [26] | retrospective | 8 | Bevacizumab | - | 2 (25%) | 0 (0%) |
| Lepore, 2014 [27] | case-control | 24* | Bevacizumab Laser coagulation | 12 | 0 (0%) | 0 (0%) |
| Moran, 2014 [28] | case-control | 28* | Bevacizumab Laser coagulation | 24 | 3 (21.4%) | 0 (0%) |
| Salman, 2014 [29] | prospective, non-randomized | 26 | Aflibercept | 12 | 1 (3.8%) | 0 (0%) |
| Yetik, 2014 [30] | prospective, non-randomized | 238 | Bevacizumab | - | 11 (4.6%) | 0 (0%) |
| Castellanos, 2013 [31] | prospective, non-randomized | 6 | Ranibizumab | 36 | 0 (0%) | 0 (0%) |
| Harder, 2013 [32] | retrospective | 49* | Bevacizumab Laser coagulation | 36 | 0 (0%) | 0 (0%) |
| Martinez-Castellanos, 2013 [33] | prospective, non-randomized | 18* | Bevacizumab | 60 | 0 (0%) | 0 (0%) |
| Sahin, 2013 [34] | retrospective | 30 | Bevacizumab | - | 2 (6.7%) | 5 (16.7%) |
| Wu, 2013 [35] | retrospective, multi-center | 162 | Bevacizumab | - | 19 (11.7%) | 4 (2.5%) |
| Dani, 2012 [36] | prospective, non-randomized | 7* | Bevacizumab w/ or w/o Laser coagulation | - | 0 (0%) | 0 (0%) |
| Harder, 2012 [37] | prospective, non-randomized | 32* | Bevacizumab Laser coagulation | 12 | - | - |
| Axer-Siegel, 2011 [38] | retrospective | 18* | Bevacizumab w/ or w/o Laser coagulation | - | 1 (10%) | 0 (0%) |
| Harder, 2011 [39] | retrospective | 23 | Bevacizumab | - | 0 (0%) | 0 (0%) |
| Mintz-Hittner, 2011 [40] | prospective, randomized | 286* | Bevacizumab Laser coagulation | 12 | 6 (4.3%) | - |
| Dorta, 2010 [41] | retrospective | 12 | Bevacizumab | - | 0 (0%) | 1 (8.3%) |
| Mintz-Hittner, 2008 [42] | retrospective | 22 | Bevacizumab | - | 0 (0%) | 0 (0%) |
Studies are sorted by date of publication.
*Not all patients included for quantitative analysis, as only selected patient groups fitted our criteria (no combined treatment, no recurrences).
**The follow-up period is only reported if follow-up was a defined period of time.